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1. Introduction 
1.1 Brain tumours in children and adults 
Primary Central Nervous System (CNS) tumours are considered to be those that originate in 
the CNS and usually remain there. Primary CNS tumours, despite not leading the cancer 
frequency rates, rank first among cancer types for the average years of life lost (Burnet et al., 
2005). By contrast with other malignancies, where research has lead to the establishment of 
more successful treatment options, the diagnosis of a CNS tumour, particularly the more 
malignant histological types, still has devastating effects on the patients and their relatives, 
not only due to the dismal prognosis of these tumours with extremely high rates of 
mortality, but also to the great morbidity that actual treatment options cause (Laughton et 
al., 2008; Mulhern et al., 2004; Silber et al., 1992).  
The estimated annual worldwide age-standardized incidence of malignant primary CNS 
tumours is 3.5 per 100,000 people, which represents more than 200,000 cases. The rate is 
slightly higher in males (3.9 per 100,000 people per year) than in females (3.1 per 100,000 
people per year) (Ferlay et al., 2008). The frequency of brain tumours is also higher in more 
developed countries (5.2 per 100,000 people per year) compared to less developed countries 
(3.0 per 100,000 people per year), probably due to diagnostic advances, as well as access to 
adequate health care in the developed regions (Ferlay et al., 2008; Wrensch et al., 2005). 
Similarly, estimated annual global age-standardized mortality of malignant primary CNS 
tumours is higher in males (3.0 per 100,000 people) than in females (2.2 per 100,000 people), 
with higher rates also in more developed countries (3.2 per 100,000 people) than in less 
developed regions (2.3 per 100,000 people) (Ferlay et al., 2008). The median age of diagnosis 
for all primary CNS tumours is 57 years, however the histology-specific median age ranges 
from 9 to 70 years ( Central Brain Tumor Registry of the United States [CBTRUS], 2010). 
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In children, CNS tumours are the second most frequent malignancy after leukaemia and are 
therefore the most common solid tumours in childhood (Jemal et al., 2009). An estimated 
3,750 new cases of childhood primary non-malignant and malignant CNS tumours are 
expected to be diagnosed in the United States each year. This number reflects an annual 
incidence rate of 4.5 cases per 100,000 people. As in adults, the rate is higher in males (4.7 
cases per 100,000 people) than in females (4.3 cases per 100,000 people) (CBTRUS, 2010). 
Importantly, malignant brain tumours are the leading cause of cancer-related death in the 
childhood (Rickert & Paulus, 2001). 
Pathologically, CNS tumours are generally classified according to the World Health 
Organization (WHO) criteria (Louis et al., 2007). There are a wide range of CNS histological 
entities, classified according to the cell morphology and the degree of malignant behaviour. 
The WHO classification (Louis et al., 2007) includes a grading scheme that is a reference for 
predicting the biological behaviour of the tumour. Grade I tumours generally have a low 
proliferative potential and the possibility of cure after surgical resection, whilst grade IV 
tumours are histologically malignant, mitotically active and necrotic, and are associated 
with rapid disease evolution contributing to the high rates of mortality and morbidity 
among malignant brain tumour patients. The incidence of different histological types of 
brain tumours varies across specific age groups (Maity et al., 2004); accordingly, the regions 
of the brain mostly affected in paediatric and adult tumours are also different. In adults and 
older children, brain tumours are mostly supratentorial (cerebrum), whereas in young 
children they are more commonly infratentorial (cerebellum) (Gottardo & Gajjar, 2008). This 
chapter will focus on malignant CNS tumours, more particularly supratentorial high-grade 
gliomas (WHO grades III and IV) and cerebellar medulloblastomas (grade IV), which are the 
most common malignant CNS tumours of adults and children, respectively. 
Brain tumour aetiology is thought to be multifactorial and is likely to vary by tumour type. 
There is a likely connection between genetics and environment, meaning that particular 
genetic susceptibilities lead to increased vulnerability to environmental factors. The only 
proven exogenous environmental cause of brain tumours, in children or adults, is ionizing 
radiation, often seen in the setting of previous radiation therapy for the treatment of a 
former malignancy (Baldwin & Preston-Martin, 2004; Bondy et al., 2008; Ohgaki & Kleihues, 
2005; Pettorini et al., 2008; Wrensch et al., 2005). Genetic susceptibility to brain tumours 
comes from rare syndromes and polymorphisms, specifically in pathways thought to be 
involved in the process of brain tumour formation. Familial tumour predisposition 
syndromes are associated with germline mutations, typically in tumour suppressor genes, 
which confer an increased susceptibility of individuals to tumour formation from childhood 
until their adult life (Ullrich, 2008). Some of the major syndromes associated with high-
grade gliomas or medulloblastomas (with genes affected by germline mutations) are 
neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (TP53) and Turcot syndrome (APC 
and MLH1/PMS2/MSH2/MSH6) (complete list in Table 1).  
1.2 High-grade glioma 
The majority of CNS tumours in all age groups are gliomas. The estimated annual incidence 
rate of gliomas in the United States is 6.0 per 100,000 people. Overall, the broad category of 
gliomas accounts for 36% of all CNS tumours and 81% of malignant lesions. In young adults 
(20-34 years), gliomas represent 39% of all CNS tumours and 86% of malignant tumours; in 
adolescents (15-19 years), 45% of all CNS tumours and 81% of malignant; whereas in  
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Syndrome Gene CNS Tumour (e.g.) 
Other Clinical 
Manifestations (e.g.) 
Neurofibromatosis 
Type 1 
NF1 
Astrocytoma, 
neurofibroma, optic 
nerve glioma 
Skin café-au-lait spots; 
axillary freckling; other 
tumours 
Neurofibromatosis 
Type 2  
NF2 
Astrocytoma, 
meningioma 
Posterior lens opacities, 
retinal hamartoma 
Tuberous sclerosis TSC1, TSC2 Giant cell astrocytoma Other tumours 
Li-Fraumeni 
syndrome 
TP53 
Astrocytoma, 
medulloblastoma 
Other tumours 
Turcot 
APC; 
MLH1, PMS2, 
MSH2, MSH6 
Medulloblastoma; 
glioblastoma  
Skin café-au-lait spots, 
colorectal polyps 
Gorlin PTCH Medulloblastoma Other tumours 
Table 1. Familial syndromes and genes involved causing increased risk of gliomas and 
medulloblastomas. Adapted from (Louis et al., 2007). 
children less than 15 years the frequency of gliomas is higher (56%), but they only account for 
74% of malignant tumours (CBTRUS, 2010). The incidence rates of gliomas by histology varies 
among age-specific groups; in children and adolescents grade I gliomas are the most common 
tumours, whereas in older patients grade IV gliomas have the highest incidence (CBTRUS, 
2010). The treatment of low-grade gliomas with surgical resection alone allows in most 
instances the possibility of cure. High-grade gliomas by contrast remain a difficult therapeutic 
challenge with a poor prognosis. Conventional treatment includes surgery, radiotherapy and 
chemotherapy, however despite improving survival times and quality of life, current 
therapeutic regimens are still unable to effect a cure. In malignant histologies, tumour cells 
infiltrate into the surrounding brain and are generally not completely removed by surgery, 
which coupled with the fact that these remaining cells are often resistant to radio- and 
chemotherapy are the main reasons for the therapeutic failure in high-grade gliomas (Imbach, 
2006). Similarly in children, surgery plays a major role in the treatment of gliomas, with the 
extent of tumour resection the most important prognostic factor in this age group. For the 
more malignant subtypes, focal radiation is used as first line adjuvant therapy, except in 
infants (Hargrave, 2009; Imbach, 2006). Both in adult and paediatric populations, histological 
type and grade of the tumour, anatomic location, extent of surgical resection, patient’s age, 
whether radiotherapy is applied, and some chemotherapy protocols have been consistently 
considered prognostic factors (Stewart & Cohen, 1998; Wrensch et al., 2005).  
The major subtypes of gliomas are astrocytomas, oligodendrogliomas and the mixed 
lineage, oligoastrocytomas. 
Astrocytoma represents a highly heterogeneous histological group of neoplasms. They 
represent about 75% of all gliomas and can occur in most parts of the brain, and are the most 
frequent gliomas of childhood (CBTRUS, 2010). While malignant astrocytomas comprise 
only 2% of all adult tumours, their malignant nature makes them the fourth greatest cancer-
related death (Davis et al., 1998). The different histological types of astrocytoma, grade I 
pilocytic, grade II diffuse, grade III anaplastic and grade IV glioblastoma vary in frequency, 
age and gender distribution, location within the brain and clinical features. The major 
malignant subtypes, anaplastic astrocytoma and glioblastoma, account respectively for 8% 
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and 51% of all gliomas, with glioblastoma representing 80% of malignant tumours 
(CBTRUS, 2010; Imbach, 2006; Louis et al., 2007; Reifenberger et al., 2006; Weingart et al., 
2006). High-grade glioma may arise de novo, and are designated primary tumours, or may be 
considered secondary tumours developing from lower grade lesions. Whereas the great 
majority of adults with diffuse astrocytoma experience malignant transformation to grade 
III and finally to grade IV astrocytoma, the long-term risk of malignant transformation in 
histologically identical neoplasms in children is less than 10% (Broniscer et al., 2007). 
Nevertheless, the majority (about 95%) of glioblastomas are primary tumours, develop very 
rapidly in elderly patients (mean 62 years) after a short clinical history and present a poorer 
prognosis (Louis et al., 2007), whereas secondary glioblastoma mostly develop in younger 
patients below the age of 45 (Louis et al., 2007). Due to its invasive nature, glioblastoma 
cannot be completely resected and despite progress in radio- and chemotherapy, less than 
half of the patients survive more than a year, making glioblastoma the CNS tumour with 
worse prognosis, for both paediatric and adult patients (Louis et al., 2007; Reifenberger et 
al., 2006). 
Oligodendroglioma account for a small subset of all gliomas (about 8%), being 
predominantly tumours of adulthood, with a peak incidence between the fourth and fifth 
decade of life, representing only 1-2% of all CNS tumours in children (CBTRUS, 2010). There 
are two grades of malignancy for oligodendrogliomas, oligodendroglioma (grade II) and 
anaplastic oligodendroglioma (grade III), with grading a significant predictor of survival. 
Precise data on the incidence of oligoastrocytoma are not available, but reported frequencies 
vary from 1-20% of all gliomas, with the higher percentage thought to be overestimated due 
to a consultation bias. These tumours arise preferentially in the cerebral hemispheres and 
mainly occur in the fifth decade of life (Bromberg & van den Bent, 2009; Louis et al., 2007; 
Reifenberger et al., 2006; van den Bent et al., 2008). Similar to oligodendrogliomas, these 
tumours can also be divided in two grades of malignancy. 
1.3 Medulloblastoma 
Medulloblastoma represents a highly malignant, invasive embryonic tumour, and is the 
most common malignant CNS tumour in children, accounting together with other 
embryonic tumours for about 1.5% of all primary CNS tumours (CBTRUS, 2010), 
representing 12-25% of childhood brain tumours and only about 0,5-1% of all brain 
neoplasms in adults (Imbach, 2006; Sarkar et al., 2005; Taylor, 2006). The peak age incidence 
is 9 years, with 70% of all medulloblastomas occurring in patients less than 16 years of age. 
In adulthood, 80% of medulloblastomas arise before the fourth decade of life and rarely 
occur after the fifth decade. About 65% of patients are male (Louis et al., 2007; Reifenberger 
et al., 2006; Taylor, 2006). The annual incidence of medulloblastoma has been estimated at 
0.5 per 100,000 children less than 15 years (CBTRUS, 2010; Reifenberger et al., 2006). 
Medulloblastoma presents predominantly neuronal differentiation. It is composed of 
densely packed small round blue cells with carrot-shaped hyperchromatic nuclei, possibly 
presenting neuroblastic rosettes which are associated with marked nuclear pleomorphism 
and high mitotic activity (Huse & Holland, 2010; Imbach, 2006; Louis et al., 2007; Taylor, 
2006). The WHO classification of CNS tumours recognizes at least five different histological 
types of medulloblastoma: classic (70-85% of the cases); desmoplastic/nodular (15% in 
paediatric medulloblastoma compared to 30-40% in adults); anaplastic (about 10-22% of 
medulloblastomas); large cell (about 2-4% of cases) and medulloblastoma with extensive 
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nodularity (about 3%) (Brandes et al., 2009; Imbach, 2006; Louis et al., 2007; Taylor, 2006). 
There is an heterogeneity among medulloblastoma histologic subtypes which exhibit a 
highly variable clinical behaviour, with the anaplastic and large cell subtypes being 
associated with worse prognosis and desmoplastic/nodular medulloblastomas portending a 
more favourable outcome (Gilbertson & Ellison, 2008; Huse & Holland, 2010; Imbach, 2006). 
About 30% of the medulloblastoma patients, particularly paediatric tumours, present 
metastasis via the cerebrospinal fluid pathways at diagnosis, whereas spread outside the 
CNS is a rare event (Carrie et al., 1994; Frost et al., 1995; Reifenberger et al., 2006). Clinical 
prognostic factors include tumour size, presence of metastasis, age, and amount of tumour 
resected (Imbach, 2006). Stratification of medulloblastoma involves distinguishing high-risk 
and standard-risk patients, with high-risk patients those aged less than 3 years, with 
incomplete surgical resection of the tumour and/or with disseminated disease (Dubuc et al., 
2010; Imbach, 2006; Louis et al., 2007). Significant advances have been made in the treatment 
of childhood medulloblastoma, with the 5-year survival raised to 60% for high-risk disease 
and 80% for standard-risk tumours, however the long-term side effects of the treatment 
modalities applied can be severe. Actual treatment includes maximal safe surgical resection 
and the use of combined radio- and chemotherapy for children older than 3 years. Most 
therapeutic approaches for high-risk patients include relatively high doses of craniospinal 
radiotherapy and aggressive chemotherapeutic regimens (Hargrave, 2009; Imbach, 2006). 
The treatment of infants with medulloblastoma remains highly problematic as radiation 
therapy is especially damaging for the developing brain of very young children. 
2. Genetic instability of malignant brain tumours 
Cancer cells usually harbour mutations in oncogenes and tumour suppressor genes. These 
may play a role in key cellular processes such as proliferation, apoptosis or angiogenesis. 
Oncogenes are genes whose deregulated activation through mutation, translocation, 
amplification or over-expression promotes tumorigenesis. Tumour suppressors, on the other 
hand, play an inhibitory role, and can be inactivated in cancer through mutation, deletion, 
methylation or transcriptional repression. Genomic instability present in cancer cells occurs 
mainly through chromosomal instability (CIN) or microsatellite instability (MSI), together 
with increased frequencies of molecular alterations in cancer regulatory genes (Negrini et 
al., 2010; Nigg, 2005). CIN refers to the high rate by which chromosome structure and 
number (by gains or losses) changes over time in cancer cells compared with normal cells 
and MSI is characterized by the expansion or contraction of the number of oligonucleotide 
repeats present in microsatellite sequences (Venkatesan & Loeb, 2005).  
2.1.1 Patterns of copy number change 
CIN is characterised by an increased frequency of chromosomal alterations, resulting in gains, 
losses, deletions, insertions, translocations, amplifications, and rearrangements. Nearly all 
human tumours display the CIN phenotype and consequently aneuploidy. Tumours with the 
CIN usually harbour mutations in oncogenes and/or tumour suppressor genes, many of 
which are involved in the regulation of transcription (Nigg, 2005). During the last decade, the 
use of genome-scale profiling techniques to identify the key genetic alterations underlying 
different tumour types allowed fundamental findings about the drivers of oncogenesis, 
providing the rationale for specific targeted therapies in these malignancies. The first studies 
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using large-scale genome profiling techniques to identify the key genetic alterations of brain 
tumours were only recently published (Kool et al., 2008; Parsons et al., 2008; The Cancer 
Genome Atlas Research Network [TCGA], 2008; Thompson et al., 2006). Nevertheless, the 
number of such studies have been increasing on the past few years, with the first studies in 
paediatric glioma patients starting to emerge (Barrow et al., 2011; Bax et al., 2010; Paugh et al., 
2010; Qu et al., 2010; Schiffman et al., 2010; Zarghooni et al., 2010).  
2.1.2 High-grade glioma 
Comprehensive mapping of the genome of adult glioblastoma has identified common 
regions of chromosomal instability and gene expression signatures, identifying frequently 
dysregulated molecular pathways (Bredel et al., 2005; de Tayrac et al., 2009; Gardina et al., 
2008; Kotliarov et al., 2006; Maher et al., 2006; Nigro et al., 2005; Parsons et al., 2008; TCGA, 
2008). The number of such studies specifically addressing childhood high-grade glioma has 
until recently been much lower. Nevertheless, several works specifically addressing these 
paediatric tumours, from ours and others groups, are beginning to emerge, providing 
increasing evidence that the paediatric high-grade glioma genome has certain key 
differences from that of histologically similar adult tumours (Barrow et al., 2011; Bax et al., 
2010; Paugh et al., 2010; Qu et al., 2010; Rao et al., 2010; Rickert et al., 2001; Schiffman et al., 
2010; K.K. Wong et al., 2006; Zarghooni et al., 2010). 
These studies have demonstrated that the retinoblastoma (RB), p53 and RTK/PI3K/MAPK 
pathways are commonly disrupted in adult and paediatric glioblastomas through various 
genetic mechanisms (TCGA, 2008; Parsons et al., 2008). Nevertheless, our data has 
demonstrated that paediatric tumours show deregulation of these core pathways by copy 
number alterations in less than half the frequency of that reported for adult tumours: 25% 
RTK/PI3K/MAPK, 19% p53 and 22% RB versus 59%, 70% and 66%, for adult glioblastoma 
(Figure 1) (Bax et al., 2010; TCGA, 2008). Even though isolated cases presented clear 
genomic events linked to activation of the sonic hedgehog (SHH) and Notch pathways 
activation, there is no evidence of consistently targeted pathways in paediatric high-grade 
gliomas. Nevertheless, low-frequency amplifications in childhood tumours included genes 
involved in cell cycle progression (CCND2, CDK4, MYC, and MYCN), receptor tyrosine 
kinases (RTKs) and ligands (EGFR, MET, IGF1R, PDGFB, and NRG1), members of the 
PI3K/MAPK pathway (PIK3C2B, PIK3C2G, PIK3R5, KRAS, AKT1, and S6K1), and p53 
pathway regulation (MDM4), some of them known to be deregulated also in adult 
glioblastoma (Figure 2) (Bax et al., 2010; Paugh et al., 2010). In addition, homozygous 
deletions of tumour suppressor genes of known importance within the adult glioblastoma 
core signalling pathways included CDKN2C, PTEN, RB1, TP53, and TP73 (Figure 1) (TCGA, 
2008; Parsons et al., 2008), albeit at considerably lower frequencies in paediatric versus adult 
tumours. These numerous low-frequency amplifications and deletions identified in 
paediatric high-grade gliomas, such as MYC/MYCN, CCND2, KRAS, and CDKN2C, suggest 
that paediatric high-grade gliomas may be molecularly more similar to secondary adult 
glioblastomas (Beroukhim et al., 2007; Maher et al., 2006). 
At the gross chromosomal level, paediatric glioblastomas can be distinguished from adult 
tumours by the more frequent gain of chromosome 1q and loss of 16q, and the relative 
scarcity of chromosome 7 gains and 10q losses. The most frequent focal amplifications are 
also different, with PDGFRA predominant in paediatric and EGFR adult tumours (Table 2). 
Moreover, paediatric cases without PDGFRA amplification seem to present overexpression 
of a specific PDGFRA-associated gene signature, which differs from that observed in adult  
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Fig. 1. Copy number alterations in core signalling Pathways in Adult and Paediatric 
Glioblastoma.  RTK/PI3K/MAPK, p53 and RB pathways are more frequently deregulated 
in adult than in paediatric glioblastomas. Adapted from (Bax et al., 2010; TCGA, 2008). 
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tumours with the 4q12 amplification (Bax et al., 2010; Martinho et al., 2009; Paugh et al., 
2010; Rickert et al., 2001; K.K. Wong et al., 2006). Even if PDGFRA amplification, 1q+ and 
16q- events are more common in paediatric patients (Qu et al., 2010; Schiffman et al., 2010; 
Zarghooni et al., 2010), they are also present in a proportion of adult tumours. Similarly 
there is a small group of paediatric high-grade gliomas containing copy number alterations 
associated with adult tumours (EGFR amplification, 7+, 10q-) (Bax et al., 2010; Paugh et al., 
2010). The deletion of CDKN2A/CDKN2B is among the most frequent focal events found in 
paediatric high-grade gliomas, nevertheless it is even more commonly present in adult 
tumours (Table 2) (Bax et al., 2010; TCGA, 2008; Paugh et al., 2010). In adults, secondary 
glioblastomas show overexpression or amplification of PDGFRA but rarely contain EGFR 
aberrations. 
 
Region 
Paediatric Glioblastoma  
(n=46)  
Adult Glioblastoma 
(n=189) 
P 
Gains    
1q 
7 
30%  
13%  
9%  
74%  
0.001 
<0.001 
Losses    
1p 
4q 
9p 
10q 
16q 
9%  
22%  
17%  
35%  
24% 
2%  
2%  
33%  
80%  
7%  
0.05 
<0.001 
<0.05 
<0.001 
0.003 
Focal amplifications    
PDGFRA 
EGFR 
16%  
4%  
11%* 
43%* 
0.2 
<0.001 
Focal deletions    
CDKN2A 20% 55%* <0.001 
* n = 206 tumours 
Table 2. Summary of copy number changes in Paediatric and Adult Glioblastoma. Adapted 
from (TCGA, 2008; Paugh et al., 2010). 
Recently, missense mutations in IDH1 were found in a significant number of adult 
glioblastomas that tend to occur mostly in younger patients with more protracted clinical 
courses (Parsons et al., 2008). These mutations were found exclusively on the R132 residue 
in the active site region of the protein (Parsons et al., 2008; Yan et al., 2009). Interestingly, a 
separate group of gliomas harbour mutations in the IDH1 homologue IDH2 at the analogous 
residue (R172). Further investigations have shown that mutations in IDH1 and IDH2 are 
present in high proportions of grade II and III astrocytic, oligodendroglial and mixed 
tumours (72 to 100%) along with secondary glioblastomas (up to 85%), but are largely 
absent in primary glioblastomas (5%) (Hartmann et al., 2009; Ichimura et al., 2009; Parsons et 
al., 2008; Watanabe et al., 2009; Yan et al., 2009). Additionally, IDH mutations are associated 
with other genomic abnormalities that are typically seen in gliomas, such as TP53 mutation 
in low-grade astrocytoma, and 1p/19q deletion in oligodendrogliomas; they are also 
mutually exclusive with EGFR amplification and chromosome 10 loss (Sanson et al., 2009; 
Watanabe et al., 2009; Yan et al., 2009). These findings suggest that, although IDH mutations 
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probably contribute to the early evolution of low-grade gliomas, remaining in the higher-
grade lesions, they seem to have no role in the underlying biology of primary glioblastoma. 
Importantly, these IDH1 hotspot mutations are not found in childhood tumours (Balss et al., 
2008; Yan et al., 2009), biologically distinguishing paediatric high-grade gliomas from adult 
secondary glioblastoma. Nevertheless, IDH1 mutations was recently found in 7 of the 20 
high-grade gliomas from older children (14-18 years) and reported to be associated with a 
favourable prognosis, as observed in adults (Pollack et al., 2010a). 
Oligodendrogliomas harbour specific copy number alterations related to response to 
therapy or prognosis, however a comparison between adult in paediatric populations is 
difficult, as paediatric oligodendrogliomas are extremely rare neoplasms. Still, up to 80% of 
adult tumours show combined loss of chromosomes 1p and 19q, associated with increased 
chemosensitivity to treatment and favourable clinical outcome (Smith et al., 2000, 1999), 
whereas deletion of these regions are rare and did not seem to anticipate a survival 
advantage in paediatric high-grade gliomas (Kreiger et al., 2005; Pollack et al., 2003).  
Another feature of childhood high-grade gliomas that is almost entirely absent from adult 
tumours is the occurrence of very few or even no detectable copy number alterations in 
paediatric tumours (Bax et al., 2010; Paugh et al., 2010). This stable genomic profile is 
independent of histologic grade or type, and seems to confer an improved survival in high-
grade glioma patients, in contrast to those patients with an amplifier genomic profile, who 
do significantly worse (Bax et al., 2010). 
2.1.3 Medulloblastoma 
Similarly to glial tumours, studies of genomic copy number alterations analysing large 
cohorts of paediatric and adult medulloblastomas have recently begun to emerge (Kool et 
al., 2008; Thompson et al., 2006; Korshunov et al., 2010).  
The most frequent and consistent genetic event reported in medulloblastoma is the partial or 
complete loss of the chromosome 17p, often in association with gain of chromosome 17q 
(resulting in the isochromosome 17q: i(17)q), occurring in approximately 30–50% of the 
medulloblastomas (Biegel et al., 1997; Bigner et al., 1988; Cogen & McDonald, 1996; Lamont 
et al., 2004; Nicholson et al., 2000; Steichen-Gersdorf et al., 1997; Capodano et al., 1994). 
Although the precise mechanism by which this genomic abnormality contributes to 
tumorigenesis and its prognostic importance remain unclear, the common deletion region of 
17p13.2-13.3 includes several confirmed and putative tumour suppressor genes, including 
TP53 (Huse & Holland, 2010). Together with the deletion of 17p, MYC amplification is a 
molecular prognostic factor of medulloblastoma (Imbach, 2006). Genomic amplifications of 
MYCN and MYC were described as characteristics of a subset of clinically aggressive 
medulloblastomas that tend to exhibit large cell/anaplastic histological features (Aldosari et 
al., 2002; Tomlinson et al., 1994).  
Recently, Korshunov and colleagues (Korshunov et al., 2010) compared a large series of 
adult and paediatric subsets of tumours, using array-based comparative genomic 
hybridization (aCGH) (34 adult and 101 paediatric patients) and validating the results in an 
independent series (112 adult and 303 childhood patients) by fluorescent in situ 
hybridization (FISH) analysis. Although frequencies of loss of 17p (either isolated or via 
i(17)q formation) were similar in both populations, isolated gains of 17q were significantly 
more frequent in children than adult patients, with monosomy of chromosome 17  
exclusively found in adults (Table 3) (Korshunov et al., 2010). Additionally, amplifications 
of MYC/MYCN prevailed in the paediatric cohort, whereas amplification of CDK6 (at 
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7q21.3), was frequently present in adult tumours and absent in paediatric 
medulloblastomas. Of note is that both MYC/MYCN and CDK6 amplifications were 
associated with poor survival in paediatric and adult populations, respectively. Besides 
chromosome 17q, alterations on additional chromosome arms were shown to be 
significantly different between adult and paediatric medulloblastoma. Gains of chromosome 
3q, 4 and 19 more frequently found in the adult tumours, while gains of 1q, 2 and 7 and loss 
of 16q was more abundant in children. The frequency of chromosome 6 deletions was 
similar across adult and childhood medulloblastoma, however the patterns of aberration 
were different, with complete loss of the chromosome and absence of concomitant 
aberrations frequently more present in paediatric medulloblastoma (Korshunov et al., 2010). 
This may explain the reason why the prognostic value of chromosome 6 deletion, a well 
established marker for favourable outcome in medulloblastoma (Clifford et al., 2006; Pfister 
et al., 2009; Thompson et al., 2006), was not found to be statistically significant for adult 
cases (Korshunov et al., 2010). A summary of the results from the validation cohort is 
presented on Table 3. 
 
Region 
Paediatric Medulloblastoma 
(n=303) 
Adult Medulloblastoma 
(n=112) 
P 
Gains    
1q 
2 
6q 
7 
17q 
24% 
15% 
11% 
33% 
17% 
9% 
6% 
3% 
14% 
2% 
<0.001 
0.02 
* 
<0.001 
** 
Losses    
6q 
17p 
12% 
4% 
15% 
4% 
* 
** 
Focal amplifications    
CDK6 
MYC/MYCN 
0.3% 
14% 
8% 
3% 
<0.001 
<0.001 
Other Alterations    
i(17)q 39% 32% ** 
* P = 0.02 for total Chromosome 6 aberrations; ** P < 0.001 for total Chromosome 17 aberrations 
Table 3. Summary of copy number changes in Paediatric and Adult Medulloblastomas 
(validation set of adult tumours by FISH analysis). Adapted from (Korshunov et al., 2010). 
2.2 Microsatellite Instability 
DNA is continuously exposed to numerous different insults, endogenous and exogenous, 
that can ultimately result in DNA mutation and alteration of cell behaviour. DNA repair 
mechanisms are therefore essential for maintaining DNA integrity and preventing 
tumorigenesis (Li, 2008; Ljungman, 2010). Consequences of the failure of these molecular 
pathways are well illustrated in colorectal cancer, mainly HNPCC where it is present in 
about 90% of the tumours. In these cancers, mismatch repair (MMR)-deficient cells adopt a 
mutator phenotype in which there is a significant increase in cellular mutation rates (Loeb, 
1991; Marra & Jiricny, 2005). The most obvious molecular signature of this mutator 
phenotype is the presence of microsatellite instability (MSI) (Fishel & Kolodner, 1995). 
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The MMR system is the major pathway responsible for repairing base-base mispairs and 
short insertion/deletion loops that arise during DNA replication and as intermediates of 
homologous recombination (Arana & Kunkel, 2010; Kunkel & Bebenek, 2000; Nigg, 2005). 
Such a mechanism is essential to the cells because the fidelity of replicating DNA 
polymerases is insufficient to generate an error-free copy of genomic DNA. Single-base 
substitutions are estimated to arise once in every 104-106 nucleotides incorporated, and 
MMR reduces the error rate to a range of 10-9 to 10-10, which ensures that the human genome 
can be duplicated without mutations (Kunkel & Bebenek, 2000). Left unrepaired, these 
structures will give rise to base-substitution and frameshift mutations, respectively (Arana 
& Kunkel, 2010; Kunkel & Bebenek, 2000; Nigg, 2005). The role of the key factors of the 
human MMR system, the MutS homologues MSH2, MSH3 and MSH6, and the MutL 
homologues MLH1 and PMS2, have begun to be elucidated (Jiricny, 2006; Li, 2008; Schofield 
& Hsieh, 2003). MSH6 competes for binding to MSH2 with MSH3 (Boland et al., 2008), 
whilst MLH1 can form heterodimers with PMS2 (Li & Modrich, 1995), PMS1 (Raschle et al., 
1999) or MLH3 (Lipkin et al., 2000); MLH1/PMS2 is the only complex with an essential role 
in mismatch correction (Nigg, 2005; Shah et al., 2010). 
Microsatellites are short DNA sequence repeats that are scattered throughout the human 
genome (Lander et al., 2001), and whose copy number varies steadily through evolution 
(Ellegren, 2004). MSI is the expansion or retraction of the number of repeats within the 
microsatellites and it is assumed to be generated by slippage of DNA polymerases during 
copying of repeats, representing a hot spot for mutagenesis (Aaltonen et al., 1994; Cahill et 
al., 1999; Ionov et al., 1993). The classification of MSI more commonly adopted takes into 
account the number of markers presenting frameshift alterations. MSI tumours are therefore 
classified as MSI-H when, comparing to germline DNA, two or more markers present allelic 
shifts, or in the absence of constitutive DNA, at least three markers are altered. When one or 
two markers present alterations tumours are classified as MSI-L; when all markers are 
normal tumours are classified as microsatellite stable (MSS) (Buhard et al., 2006; Umar et al., 
2004; Y.F. Wong et al., 2006). In parallel with this classification, an alternative qualitative 
distinction of MSI, which considers the size of the allelic shifts in the markers, has been 
proposed (Giunti et al., 2009; Oda et al., 2005). Samples presenting small length changes (6 
bp) are designed Type A MSI whereas those with more extreme variations are defined as 
Type B MSI.  
The presence and frequency of MSI in brain tumours is a controversial and poorly studied 
issue. Previous studies have evaluated the presence of MSI in brain tumours, particularly in 
gliomas, while in medulloblastomas MSI status has not been properly addressed. Reports in 
the literature describe the absence or rare incidence of MSI in adult patients, while in 
children results have been contradictory, with reported frequencies in paediatric gliomas 
varying between 0 and 44% (Alonso et al., 2001; Amariglio et al., 1995; Cheng et al., 1999; 
Dams et al., 1995; Eckert et al., 2007; Izumoto et al., 1997; Kanamori et al., 2000; Leung et al., 
1998; Martinez et al., 2005; Sobrido et al., 2000; Vladimirova et al., 2007). Importantly, the 
methodologies for determining MSI have been highly diverse, making it difficult to draw 
accurate conclusions (Table 4). To clarify the role of MSI in paediatric versus adult malignant 
brain tumours, our group has used a highly sensitive and robust panel of MSI markers and 
studied series of high-grade glioma and medulloblastoma of adult and paediatric samples 
for the presence of MSI (Viana-Pereira et al., 2009, 2011). In our study of high-grade 
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Reference 
Age 
(years)
Number of 
cases 
MSI (%) Markers 
QMVR or 
comparison with 
germline DNA 
Pollack et al., 
2010b 
<21 68 3 (4.4%) 
Mononucleotide and 
Polynucleotide* 
N/A 
Maxwell et 
al, 2008 
N/A 52 8 (15.4%) Mononucleotide QMVR 
Vladimirova 
et al., 2007 
<18 126 4 (3.2%) Mononucleotide - 
Eckert et al., 
2007 
<22 71 0 
Mononucleotide N/A 
<22 553 1 (0.2%) 
Martinez et 
al., 2005 
<18 1 0 Mononucleotide and 
Polynucleotide 
Comparison with 
germline DNA  >18 108 6 (5.6%) 
Alonso et al., 
2001 
<21 102 16 (15.7%) 
Mononucleotide No 
>21 104 0 
Kanamori et 
al., 2000 
13-19 6 2 (33.3%) 
Mononucleotide and 
Polynucleotide 
Comparison with 
germline DNA 
20-29 8 0 
>30 66 0 
Sobrido et al., 
2000 
N/A 56 10 (17.9%) Polynucleotide 
Comparison with 
germline DNA 
*NCI recommended panel of markers (2 mononucleotide markers: BAT26 and BAT25; and 3 
dinucleotide markers: D2S123, D5S346 and D17S250) 
N/A – not available 
Table 4. Summary of relevant studies reporting MSI analysis in brain tumours after the year 
2000. 
gliomas, the frequency of MSI was significantly higher in paediatric than adult tumours 
(Viana-Pereira et al., 2011), reflecting the bulk of the previously published data (Alonso et 
al., 2001; Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005). 
On the other hand, in medulloblastomas, no difference was observed in MSI frequency 
between adult and paediatric tumours, suggesting that the presence of MSI in these tumours 
is not age-related (Viana-Pereira et al., 2009). Overall, it seems that there are less molecular 
differences between adult and paediatric medulloblastomas than those reported in high-
grade gliomas, in concordance with our MSI data.  
One of the key considerations in the assessment of MSI is in the use of mononucleotides 
versus polynucleotides in the panel of markers used. In our studies we used a pentaplex of 
quasimonomorphic mononucleotide markers (NR27, NR21, NR24, BAT25 and BAT26), 
which is currently regarded as the most sensitive panel of markers available, with distinct 
advantages over the classic National Cancer Institute panel of markers (2 mononucleotide 
markers: BAT26 and BAT25; and 3 dinucleotide markers: D2S123, D5S346 and D17S250) to 
the determine MSI in populations of different ethnicities and in different types of human 
tumours (Buhard et al., 2004; Buhard et al., 2006; Goel et al., 2010; Y.F. Wong et al., 2006). 
Importantly, the use of quasimonomorphic mononucleotide markers overcomes the need 
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for using matching germline DNA, required when using dinucleotide polymorphic markers. 
Despite this, still there is the need for optimization of the quasi-monomorphic variation 
range (QMVR) for each marker, as the allelic size estimation for these quasimonomorphic 
markers can be influenced by the use of specific reagents or the sequencing machine (Goel et 
al., 2010).  
Previous studies have established MSI frequencies in gliomas using polynucleotide markers 
only, with frequencies ranging from 0 to 37% (Amariglio et al., 1995; Dams et al., 1995; 
Izumoto et al., 1997; Sobrido et al., 2000). Including both mononucleotide and 
polynucleotides repeat markers did not improve consistency, with contrasting results 
varying between 0 and 44% in paediatric gliomas cohorts or between 0 and 18% in adult 
tumours (Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005; 
Pollack et al., 2010b). Using mononucleotides only also provided contradictory results of 0 
to 27% MSI in paediatric gliomas (Alonso et al., 2001; Eckert et al., 2007; Vladimirova et al., 
2007). In addition to the heterogeneity of markers used to assess MSI frequency that likely 
accounts for the majority of variability in the data, many of the previous studies did not 
refer the establishment of a QMVR (for quasimonomorphic mononucleotide markers) or a 
direct comparison between tumour and germline DNA (for other markers).  
In contrast to colorectal cancer, which presents mainly Type B MSI, we and others have 
shown that high-grade gliomas harbour Type A MSI (Giunti et al., 2009; Viana-Pereira et al., 
2009, 2011). Moreover, we have observed that both MSI-positive medulloblastoma and high-
grade glioma presented small length alterations within the microsatellites and hypothesise 
that this can also contribute for the high variation frequency of MSI in brain tumours 
reported in the literature (Alonso et al., 2001; Amariglio et al., 1995; Cheng et al., 1999; Dams 
et al., 1995; Eckert et al., 2007; Izumoto et al., 1997; Kanamori et al., 2000; Leung et al., 1998; 
Martinez et al., 2005; Sobrido et al., 2000; Vladimirova et al., 2007).  
Importantly, the MSI-positive paediatric high-grade glioma mostly presented a stable 
genomic profile at the chromosomal level, even if microsatellite and chromosomal instability 
were not mutually exclusive. As mentioned above, the presence of a proportion of tumours 
with few or absent copy number alterations distinguishes paediatric high-grade gliomas 
from their adult counterparts and therefore we hypothesise that MSI might represent an 
alternative form of genetic instability, at least in a proportion of these paediatric tumours 
with no gross chromosome number alterations. 
Mismatch repair deficiencies have been associated with paediatric brain tumours in a 
hereditary context. Case reports have described MMR germline mutations combined with 
NF1-like clinical features in children presenting medulloblastoma or high-grade glioma, 
described as a “mismatch repair-deficiency (MMR-D) syndrome” (summary in Table 5)  
(Agostini et al., 2005; De Rosa et al., 2000; Giunti et al., 2009; Hegde et al., 2005; Kruger et al., 
2008; Menko et al., 2004; Ostergaard et al., 2005; Poley et al., 2007; Roy et al., 2009; Scott et 
al., 2007; Toledano et al., 2009; Viana-Pereira et al., submitted; Wagner et al., 2003; Wang et 
al., 1999). Also in our study there was a MSI-H paediatric high-grade glioma with clinical 
characteristics of NF1 (multiple café-au-lait spots). Even though there was no constitutional 
DNA available for evaluation of MMR germline mutations, data imply that this patient 
probably present a MSH6 germline mutation, harbouring a MMR-D syndrome (de Leeuw et 
al., 2000).  
Due to the widespread presence of microsatellites in DNA, mutations are expected to 
accumulate in the genome of tumour cells due to MMR deficiency, with some alterations  
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Family 
Malignancy 
Age at 
diagnosis
Café-au-
lait spots
Affected 
gene 
Reference 
1 
 
AML 
Medulloblastoma 
6 
7 
Yes MLH1 Wang et al., 1999 
2 
 
 
 
Anaplastic 
oligodendroglioma/ 
Colorectal cancer 
14 / 17 
 
18 
NS 
PMS2 De Rosa et al., 2000 
Neuroblastoma 13 NS 
3 
 
Oligodendroglioma 
Rectosigmoid carcinoma 
10 
12 
Yes MSH6 Menko et al., 2004 
4 Glioblastoma 8 Yes MSH6 Hegde et al., 2005 
5 
 
 
Duodenal adenocarcinoma 
Colonic adenoma 
Glioblastoma 
16 
16 
17 
Yes PMS2 Agostini et al., 2005 
6 
 
 
Pilocytic astrocytoma 
Lymphoma 
9 
10 
Yes 
MSH6 
Ostergaard et al., 
2005 
Spinal glioblastoma 2 Yes 
7 
 
Glioblastoma 
Wilms tumour 
4 
4 
Yes MLH1 
Wagner et al., 2003 
Poley et al., 2007 
8 
 
 
 
Lymphoma 
Anaplastic 
oligodendroglioma 
4 
6 
 
Yes 
MSH6? Poley et al., 2007 
Medulloblastoma 6 Yes 
9 
 
 
Medulloblastoma 
AML 
Colon carcinomas 
7 
10 
13 
Yes MSH6 Scott et al., 2007 
10 
 
 
 
 
 
Glioblastoma 6 Yes 
PMS2 Kruger et al., 2008 
Glioblastoma 
Colorectal cancer 
Small bowel cancer 
Urotel carcinoma 
6 
15 
15 
15 
Yes 
Glioblastoma 9 Yes 
11 Glioblastoma 10 Yes PMS2 Giunti et al., 2009 
12 
 
Glioblastoma 4 NS MLH1 
Giunti et al., 2009 
Glioblastoma 12 NS NS 
13 
 
Colorectal cancer 
Astrocytoma WHOII 
14 
14 
Yes MSH2 
Toledano et al., 2009 
Anaplastic astrocytoma 13 Yes NS 
14 Medulloblastoma 
Duodenal adenocarcinoma 
 
16 
Yes PMS2 Roy et al., 2009 
15 
Glioblastoma 3 Yes MLH6? 
Viana-Pereira et al., 
submitted 
Table 5. Cases reported in the literature with MMR-D associated with brain tumours, 
including the likely MMR-D cases found in our studies. 
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potentially contributing to tumorigenesis (Duval & Hamelin, 2002). Genes thought to 
harbour mutations in microsatellites due to the MSI phenotype are commonly designated 
MSI target genes. There are numerous MSI target genes described, however the relevance of 
several of them in cancer is not clear-cut (Mori et al., 2001; Woerner et al., 2003). In brain 
tumours, only a small number of the “classical” mutated MSI target genes have been 
reported: IGFIIR (Leung et al., 1998) and PTEN (Kanamori et al., 2000), each of them in a 
single case of MSI high-grade gliomas, and TGFRII, reported in 71% of samples (Izumoto et 
al., 1997), although this result was never confirmed (Kanamori et al., 2000; Leung et al., 
1998). We identified four additional alterations, not previously reported in brain tumours, 
all in genes involved in different DNA repair pathways: mutations in the MBD4, DNAPKcs, 
and MSH6 genes and a polymorphism in MRE11 (Viana-Pereira et al., 2009, 2011).  
In summary, MSI is present in a subset of medulloblastomas and paediatric high-grade 
gliomas associated with molecular alterations distinctive of this phenotype, suggesting a 
potentially new genetic pathway correlated with the development of these tumours. As MSI 
is associated in other tumour types to a differential response to chemotherapy, the presence 
of MSI even in a small subset of brain tumours may have important translational 
implications in these extraordinarily treatment refractory malignancies. 
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